ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling
Abstract The factors that affect hypomethylating agents (HMAs) sensitivity in myelodysplastic syndrome (MDS) are complex and multifaceted. They include DNA methylation, gene expression, mutation, etc. However, the underlying mechanisms are still not clearly illustrated. In the present work, ABAT gen...
Main Authors: | Guangjie Zhao, Shuang Li, Qian Wang, Wanlin Wu, Xuewei Fu, Chen Zhu, Wei Wang, Xiaoqin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-09-01
|
Series: | Cell Death Discovery |
Online Access: | https://doi.org/10.1038/s41420-022-01170-7 |
Similar Items
-
P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: K. Chien, et al.
Published: (2022-06-01) -
P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
by: Samuel Urrutia, et al.
Published: (2023-08-01) -
Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
by: Vincent G. Sorrentino, et al.
Published: (2021-07-01) -
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
by: Juliane Grimm, et al.
Published: (2022-08-01) -
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
by: Rami S. Komrokji, et al.
Published: (2022-11-01)